NASDAQ Composite opens in less than two hours and Catalyst Pharmaceuticals’s premarket value is already 2.08% up.
The last session, nASDAQ Composite ended with Catalyst Pharmaceuticals dropping 2.03% to $3.37. NASDAQ Composite fell 0.38% to $12,850.22, following last session’s downward trend on what was a somewhat rough trend trading session.
Catalyst Pharmaceuticals’s last close was $3.44, 56.68% under its 52-week high of $5.28.
Catalyst Pharmaceuticals’s Sales
Catalyst Pharmaceuticals’s sales growth is 11.6% for the ongoing quarter and 4.6% for the next. The company’s growth estimates for the ongoing quarter is 25% and a drop 10% for the next.
Catalyst Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth declined by 5.1%, now sitting on 118.18M for the twelve trailing months.
Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $3.37 at 08:20 EST, way under its 52-week high of $5.28 and way higher than its 52-week low of $2.55.
Catalyst Pharmaceuticals’s Moving Average
Catalyst Pharmaceuticals’s value is below its 50-day moving average of $3.51 and under its 200-day moving average of $3.73.
Volatility
Catalyst Pharmaceuticals’s last day, last week, and last month’s average volatility was a positive 0.58%, a negative 0.81%, and a negative 0.06%, respectively.
Catalyst Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 4.11%, 3.95%, and 5.23%, respectively.
